Other coronary interventions

Case-based discussions and the very first presentation of data from two meta-analyses combine in an interactive session that aims to help clinicians navigate their way through the use of acute and chronic antithrombotics.

Watch this interview of Tom Johnson by Jan McCloud recorded for EuroPCR 2022 to understand how MLD MAX workflow improves decision-making, efficiency, and product utilisation, and how it can lower radiation exposure while keeping the contrast use constant when compared to angiography-guided PCI.

View more videos and course...

Watch this discussion between Maciej Lesiak, Alexandre Avran, and Luo Jianfang to get an update on the development of complex PCI access tools and strategy, to find out more about some new tools to solve old (and chronic) problems, and to learn more about the clinical...

The recently published ADAPT-DES sub-study addressed the question of early and long-term impact of contrast-associated acute kidney injury (CA-AKI) on net adverse clinical events. In addition, the authors defined risk factors for the development of CA-AKI in all-comers using contemporary PCI techniques.

Techniques to manage simultaneously severe calcified aortic stenosis and severe heavily calcified ostial RCA disease combining TAVI and ROTABLATION.

The RESTORE trial aimed to evaluate the clinical value of short-term postoperative anticoagulation with Rivaroxaban 10 mg daily for 7 days as compared with placebo, in reducing RAO at 24 hours and 30 days.

The aim of the current study was to evaluate whether administration of nitroglycerin at the beginning or end of a trans-radial approach procedure would preserve radial artery patency.

CRUNCH registry aimed to investigate the safety and efficacy of intravascular lithotripsy in the setting of resistant stent under expansion due to underlying calcific plaques.

Dejan Milasinovic provides his take on the EDIT-CMD Randomized Clinical Trial which aimed to assess the efficacy of diltiazem to improve coronary vasomotor dysfunction in angina and nonobstructive coronary arteries.

Elad Asher provides his take on this phase IIb trial in healthy people ages 50 to 80 showing that the novel intravenous treatment bentracimab significantly restored platelet function in patients receiving oral P2Y12 inhibitor ticagrelor. The clinical trial was presented by Deepak L. Bhatt at the American College of Cardiology...